Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma.
We conducted a double retroviral vector (RV) gene marking trial to test for the possible contribution to relapse of follicular non-Hodgkin's lymphoma (FNHL) cells present in bone marrow (BM) and peripheral blood (PB) grafts used for hematopoietic reconstitution of patients undergoing myelaoblative chemotherapy and autologous transplant. CD34 positive selection using the CellPro Ceprate CD34 column was performed on PB mononuclear cells obtained after cyclophosphamide/G-CSF mobilization. CD34 positive cells were exposed for 4-6 hours to the LNL6 or G1 Na RV in the absence of growth factors or stromal monolayers. One week later, BM mononuclear cells were similarly processed. Patients then received total body irradiation (TBI), cyclophosphamide, and etoposide followed by infusion of both PB and BM CD34 positive cells. Semiquantitative Southern blot analysis of DNA t(14;18) amplification products showed approximately a three log reduction in t(14;18) positive cells after CD34 positive selection. The first patient showed evidence of engraftment with RV positive BM and PB cells for 9 months. He relapsed one year after transplant. At relapse, one year after transplant, he had lost evidence of RV positive cells in ficolled mononuclear BM and PB cells as well as in CD19 positive cells. The second and third patients showed evidence of engraftment with RV positive cells up to 9 and 6 months post BMT respectively. The second and third patients are still in clinical remission. Our results demonstrate engraftment of RV transduced hematopoietic cells in the PB and BM for up to 9 months.
South Texas Cancer Institute, San Antonio 78229, USA.
C R
CR
Bachier
R E
RE
Giles
D
D
Ellerson
E G
EG
Hanania
F
F
Garcia-Sanchez
M
M
Andreeff
F
F
Cabanillas
R
R
Champlin
R
R
Choudhury
R
R
Berenson
S
S
Heimfeld
A B
AB
Deisseroth
D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005822:Genetic Vectors; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology / Q000821:virology*; D006801:Humans; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000628:therapy; D008875:Middle Aged; D012190:Retroviridae / Q000235:genetics*; D014161:Transduction, Genetic; D016896:Treatment Outcome
D018952:Antigens, CD34